Associations of exposure to perfluoroalkyl substances with thyroid hormone concentrations and birth size

Xiao, Christina; Grandjean, Philippe; Valvi, Damaskini; Nielsen, Flemming; Jensen, Tina Kold; Weihe, Pal; Oulhote, Youssef

Published in:
The Journal of clinical endocrinology and metabolism

DOI:
10.1210/clinem/dgz147

Publication date:
2020

Document version
Accepted manuscript

Citation for published version (APA):

Terms of use
This work is brought to you by the University of Southern Denmark through the SDU Research Portal. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:

• You may download this work for personal use only.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to puresupport@bib.sdu.dk

Download date: 10. May. 2021
Associations of exposure to perfluoroalkyl substances with thyroid hormone concentrations and birth size

Christina Xiao\textsuperscript{1,2}, Philippe Grandjean\textsuperscript{1,3}, Damaskini Valvi\textsuperscript{4}, Flemming Nielsen\textsuperscript{3}, Tina Kold Jensen\textsuperscript{3}, Pal Weihe\textsuperscript{5}, Youssef Oulhote\textsuperscript{1,6}

1) Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, MA, United States.
2) EHESP-School of Public Health, Sorbonne Paris Cité, Rennes, France.
3) Department of Environmental Medicine, University of Southern Denmark, Odense, Denmark.
4) Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
5) The Faroese Hospital System, Tórshavn, Faroe Islands.
6) Department of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts at Amherst, MA, United States.

Keywords: Perfluoroalkyl substances, fetal development, thyroid hormones, pregnant women, mediation analysis, birth outcomes
Corresponding author’s contact information:

Name: Christina Xiao

Email: cxiao94@gmail.com

Telephone: +33 7 61 70 33 22

Address: Harvard School of Public Health, Department of Environmental Health

665 Huntington Ave, Building 1, Room 1312, Boston, MA 02115

Reprint requests should be addressed to: Christina Xiao, Harvard School of Public Health, Department of Environmental Health, 665 Huntington Ave, Building 1, Room 1312, Boston, MA 02115

Grants and fellowships: This work was supported by the National Institute of Environmental Health Sciences (ES011681, ES012199 and ES027706) and the Danish Environmental Protection Agency as part of the environmental support program DANCEA (Danish Cooperation for Environment in the Arctic).

Disclosure summary: P.G. served as a health expert for the State of Minnesota in a lawsuit against a PFAS-producing company. All other authors declare they have no actual or potential competing financial interests.
Abstract

**Background:** Adequate thyroid function during pregnancy is essential for optimal fetal growth. Gestational exposure to perfluoroalkyl substances (PFASs) can negatively affect birth size and disrupt maternal and neonatal thyroid function, although the interrelationship is unclear.

**Objective:** We aimed to quantify the associations between maternal serum-PFAS concentrations and birth weight, birth length, and cranial circumference. We also aimed to estimate associations between PFAS and thyroid hormone (TH) concentrations, thereby elucidating whether THs potentially mediate the associations between PFAS concentrations and birth size.

**Methods:** We studied a population-based prospective cohort of 172 mother-singleton pairs from the Faroe Islands. Twelve PFAS were measured in maternal serum obtained at 34 weeks of gestation. THs were measured in maternal and cord serum. Associations between PFAS concentrations and birth size and TH concentrations were estimated using multivariable linear regressions. Sex-stratified analyses along with a mediation analysis were performed to estimate potential mediating effects of THs in the association between PFAS and birth outcomes.

**Results:** Several PFASs were negatively associated with birth weight, length, and head circumference, and a general positive association between maternal serum-PFASs and cord serum-thyroid stimulating hormone was found. For instance, a doubling in perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) was associated with a 53% (95% CI: 18%, 99%) and 40% (95% CI: 8%, 81%) increases in thyroid stimulating hormone concentrations, respectively. There was little evidence of sexually dimorphic associations. Overall, THs were not found to mediate associations between PFASs and birth size.
Conclusion: In this study, several PFASs were negatively associated with birth size and increased THs, which however did not explain lower birth weight among children exposed to PFAS.
Précis

Perfluoroalkyl substances (PFAS) were negatively associated with birth size and positively associated with thyroid stimulating hormone; the latter did not mediate PFAS and birth size associations.
Introduction

Perfluoroalkyl substances (PFAS) are a group of synthetically manufactured chemicals that are highly persistent in the environment and bioaccumulate in food chains (1,2). Main sources of exposure in the general population include consumer products, seafood, house dust, and drinking water (3–6). Early life stages are particularly vulnerable to PFAS exposure (7), and current evidence suggests that PFAS exposures negatively impact the regulation and development of metabolic, immune, and neurological systems in pregnant women and infants (8–10).

PFAS such as perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) have been found to be inversely associated with fetal growth outcomes such as birth weight, birth length, and/or head circumference in many previous birth cohort studies (10–24), including in an earlier study of the Faroese population (25). Such a relationship between PFAS exposure and birth size may be mediated by thyroid hormones (THs), which play a significant role in regulating metabolic functions (26). One way PFAS can disrupt regulation of THs is through the hypothalamic–pituitary–thyroid (HPT) axis. It was found that PFOS can affect TH production through disruption of the hypothalamic–pituitary–thyroid (HPT) axis of zebrafish larvae and alter the secretion and function of major thyroid hormones that play a key role in energy metabolism, including thyroid stimulating hormone (TSH), free thyroxine (FT₄), thyroxine (T₄), and free triiodothyronine (FT₃) (27).

Recent systematic reviews have found that PFAS can potentially impact both maternal TH levels during gestation and newborn TH levels at birth (8,9,28). In particular, PFOS and PFOA have been found to be positively associated with maternal and cord TSH levels (29–32). Other PFAS,
such as perfluorononanoic acid (PFNA) were reported to be positively associated with maternal TSH (32,33), and inversely associated with total T₃, T₄, and FT₄, whereas perfluoroundecanoic acid (PFUnDA) and perfluorododecanoic acid (PFDoDA) have been found to be negatively associated with maternal FT₄ and total T₄ (34,35).

From the associations and possible biological pathways between PFAS, thyroid function, and birth size measures, we hypothesize that THs may mediate the relationship between PFAS and birth size. We assessed associations between PFAS exposures and birth size within a prospective cohort study of the Faroese population with a wide range of PFAS exposure levels. We also determined to what extent these associations were mediated by either maternal or cord serum TH concentrations, and the possible modification by infant sex.

Methods

Population and study design
We used data from a cohort study conducted in the Faroe Islands that included measurements of THs (n=182). This population is known to consume pilot whale meat, thereby causing elevated PFAS exposures (36). Data were collected over a 12-month period in 1994-1995 and consisted of 182 singleton births at the National Hospital in Torshavn. Exclusion criteria included any children born before the 36th week of gestation, weighing less than 2,500 grams, or any congenital neurological disease. Maternal serum was obtained during the last prenatal care visit at 34 weeks of gestation. Cord serum was collected at delivery by drawing blood from the umbilical cord using heparinized syringes. Obstetric information, including birth size, parity, maternal age, pre-pregnancy BMI, gestational weight gain, gestational diabetes, and gestational
age were abstracted from the hospital’s medical records. Demographic and other relevant information were obtained using in-person interviews and standard questionnaires, with questions about the mother’s medical history, indicators of socioeconomic status (SES), and current health, both before and after giving birth. Of note, this study population is rather homogeneous in terms of SES. The study design and methods were approved by the Faroese Ethical Review committee. All participating mothers provided their written informed consent. Additional information about study methods as well as exposure and outcome measurements can be found elsewhere (37,38).

Birth size outcome measurements

Weight, length, and head circumference were measured at birth. These variables were standardized to z-scores specific for gestational age and sex using the recent INTERGROWTH-21st fetal growth standard. The INTERGROWTH-21st fetal growth standard is based on a multi-center, international population-based cohort of 20,486 pregnant women and their offspring from eight countries including the U.S., and utilized the same methodology as the 2006 WHO Growth Reference to provide growth standard curves specific for fetuses (39). For the weight, length and head circumference z-scores calculation, we used the “Healthy Birth, Growth, and Development (hbgd)” package in R (40).

PFAS exposure biomarkers

Methods for analyzing PFAS exposure have been described previously (37). Separated serum samples were stored at -80 °C until analysis. Seventeen PFAS, including PFAS precursors, were quantified using online solid-phase extraction along with high-pressure liquid chromatography
and tandem mass spectrometry (41). The extraction was performed on a Thermo Scientific EQuan MAX system, consisting of two Accela HPLC pumps (Thermo Scientific, San José, CA) and a PAL autosampler module (CTC analysis AG, Zwingen, Switzerland). The tandem mass spectrometer was a TSQ Quantum Ultra Triple Stage Quadropole with heated electrospray ionization (Thermo Scientific, San Jose, CA). A calibration curve serum and solvent blanks, as well as quality control samples were included in each batch of samples analyzed. Imprecision within batches was < 9% for all the analytes and the limit of quantitation (LOQ) was 0.03 ng/mL for all compounds.

**Maternal and cord serum TH concentrations**

TSH was measured using time-resolved fluoroimmunoassay in maternal and cord serum, while FT₄ and FT₃ were quantified using a radioimmunoassay after dialysis to equilibrium. Free triiodothyronine resin uptake (T₃RU) is also used to measure thyroid hormone binding capacity, whereas free T₄ index (FTI) corrects T₄ estimates for abnormalities in serum binding properties (42). Thus, T₃RU and total T₄ were also quantified by radioimmunoassay, the results of which were then used to calculate FTI values (43).

**Covariates**

Complete data on exposures, THs, and birth size measures were available for 172 participants. Confounders were determined a priori based on associations between PFAS and birth size measures from previous studies (14,15,18,25), as illustrated on the directed acyclic graph (DAG) in the Supplemental Material (44). Models were adjusted for the following covariates: sex of the fetus (female/male), gestational age in weeks (treated as a continuous variable), maternal
education (coded as having or not having received higher education), maternal pre-pregnancy body mass index (BMI) (treated as a continuous variable), parity (treated as a continuous variable), smoking status during pregnancy (smoker/nonsmoker), alcohol consumption during pregnancy (some/none), along with potential chemical exposures that may affect TH levels or birth size measures (maternal hair-mercury and maternal serum concentrations of the sum of polychlorinated biphenyl (PCBs)) congeners 138, 153, and 180.

**Data Analysis**

Serum-PFAS concentrations were included in subsequent analysis if they were detected in at least 30% of participants. PFAS exposures and TH data were considered as continuous variables and log-transformed to approximate a Gaussian distribution and limit the influence of outliers. We generated descriptive tables for THs and PFAS concentrations and conducted a bivariate Pearson correlation test. We used generalized additive models to examine potential non-linear relationships between PFAS and birth size, but no significant departure from linearity was observed. We therefore performed separate crude and adjusted multiple linear regression models with important covariates between log$_2$-transformed PFAS concentrations and birth weight, birth length, and head circumference z-scores. To convert z-scores back to raw birth size values, the following formula was used:

$$\text{(1) Raw score} = \mu + Z\sigma$$

Where $\mu$ is the mean, $Z$ is the z-score, and $\sigma$ is the standard deviation of the Faroese cohort (values can be found in Table 3).

Additional analyses explored potential sexually dimorphic effects through a cross-product term interaction based on the child’s gender for each of the associations detailed above.
TH concentrations were natural log-transformed to quantify the percent change in mean TH levels for each doubling in PFAS exposure. To calculate the percent change, we used the following formula:

\[(1) \text{ } \% \text{ change} = (e^\beta - 1) \times 100\]

Where \( \beta \) is the regression coefficient.

To investigate the potential for THs for mediating the observed associations between PFAS and birth size measures, we conducted a formal mediation analysis. We calculated 1) the average causal mediated effect (ACME) which represents the estimated average change in the outcome that is mediated through changes in TH levels, i.e. the natural indirect effect; 2) the average direct effect (ADE) which represents the unmediated effect, or the effect of the exposure (PFAS) on the birth size measures that is not mediated through changes in TH levels (mediated through other mechanisms), i.e. natural direct effect; and 3) the total effect (TE) calculated as the sum of ADE and ACME, and percent mediated (PM) calculated as the ratio of the indirect to the total effect (ACME/TE) \times 100\% \ (45). We used Monte Carlo approximation based on the asymptotic sampling distribution (n=1000) \ (46)\ to compute confidence intervals. Data analyses were conducted using Stata \( (47) \) as well as the mediation \( (45) \) and mgcv \( (48) \) packages in R \( (49) \).

**Results**

Table 1 details child and maternal characteristics for the 172 mother-child pairs assessed for PFAS and TH levels. 51\% of the cohort was comprised of boys and 49\% of the cohort was comprised of girls. The average gestational age was 39.6 weeks (SD=1.3), the average birth
weight was 3672 g (SD=485), and the average birth length 53.0 cm (SD=2.1). The average maternal age was 28.1 years (SD=5.6) and about 22% of mothers had received at least college education. The average maternal pre-pregnancy BMI was 23.1 (SD=3.5), and approximately one-third of the women were primiparous. The percentage of women who consumed alcohol or who smoked during pregnancy was 31.3% and 12.8%, respectively.

Insert Table 1. [HERE]

Table 2 shows the distribution of PFAS concentrations. Twelve PFAS were detected in more than 30% of the samples (Table 2). PFOA and PFOS exhibited higher concentrations than other PFAS. Many PFAS showed significantly positive correlations to other PFAS. The strongest correlations were found between PFNA and perfluorodecanoic acid (PFDA) (0.82) as well as PFDA and PFUnDA (0.87); perfluoroheptanoic acid (PFHpA) and PFDoDA were weakly correlated with most other PFAS (range of correlations: -0.07, 0.33) (44).

Insert Table 2. [HERE]

Table 3 displays the distribution of maternal and TH concentrations as well as fetal growth outcomes. We did not find mean values outside the normal range. Pearson correlation coefficients between maternal T₄ and FTI were highly correlated (0.82), as were cord serum T₄ and FTI (0.84). Maternal T₄ and T₃RU displayed a negative correlation (-0.39), as did cord T₄ and T₃RU (-0.42). In general, maternal and fetal THs were weakly to moderately correlated.
(range of correlations: -0.28, 0.31) (44). Among fetal growth outcomes, birth length and birth weight were highly correlated (0.74), as were birth weight and head circumference (0.75) (44).

**Insert Table 3. [HERE]**

**Associations between PFAS and birth size measures**

Several PFAS were inversely associated with birth length, birth weight, and cranial circumference (Figure 1). For instance, a doubling in serum perfluorohexane sulfonate (PFHxS) concentrations was negatively associated with all three birth size measures: birth weight (-0.51 SD; 95% CI: -0.85, -0.18), birth length (-0.40 SD; 95% CI: -0.72, -0.09), and head circumference (-0.36 SD; 95% CI: -0.72, 0). This translates into a decrease of 246 g, 0.82 cm, and 0.49 cm, respectively. Likewise, a two-fold increase in PFOS concentrations was negatively associated with birth weight (-0.47 SD; 95% CI: -0.85, -0.04) and birth length (-0.33 SD; 95% CI: -0.69, 0.03), which corresponds to a decrease of 227 g and 0.67 cm, respectively. We observed similar yet slightly weaker inverse associations between PFNA, PFDA, and PFOA with birth weight, and between PFDA and perfluoroheptane sulfonate (PFHpS) with birth length (Figure 1). No other association was observed for other PFAS in relation to the same fetal growth outcomes. In addition, there was no evidence of effect modification by child sex (Figure 1). Complete estimates for the numerical data are available in Supplemental Material (44).

**Insert Figure 1. [HERE]**

**Associations between PFAS and maternal and cord TH concentrations**
Some PFAS were positively associated with maternal TSH, with PFNA, PFOS, PFDA, and PFOA showing the strongest estimates; however, these increases did not reach the level of significance (Figure 2). For instance, a doubling in PFNA and PFOS was associated with a 20% (95% CI: -5%, 52%) and 16% (95% CI: -8%, 47%) increase in maternal TSH concentrations, respectively (44).

PFOS exhibited sexually dimorphic associations (p-interaction <0.1 but > 0.05) with maternal TSH and FTI levels (Figure 3); we also found a similar pattern between PFOA and maternal FTI. In mothers bearing female fetuses, PFOS was positively associated with maternal TSH, T₄, and FTI levels, while there was a negative association for mothers bearing male fetuses. For instance, a doubling in gestational PFOS concentrations was associated with a 54% (95% CI: 11%, 114%) increase in maternal TSH levels in mothers bearing female fetuses, in comparison to a decrease by 6% (95% CI: -30%, 25%) in mothers bearing male fetuses (p_EM=0.09) (44). Likewise, higher PFOA concentrations were positively associated with maternal TSH and FTI levels in mothers bearing female fetuses, while the association was negative in mothers bearing male fetuses. A doubling in the gestational PFOA concentrations was associated with a 5% (95% CI: -2%, 13%) increase in maternal FTI levels in mothers bearing female fetuses, in comparison to a decrease by 7% (95% CI: -14%, 1%) in mothers bearing male fetuses (p_EM=0.02) (44). We did not observe consistent patterns of sexually dimorphic associations for other PFAS concentrations and maternal TH levels.

Insert Figure 2. [HERE]
Regarding cord TH levels, there was a consistent positive association between PFAS and cord TSH. A doubling in PFOS, PFOA, PFDA, PFNA, and perfluorooctane sulfonamide (FOSA) was associated with 53% (95% CI: 18%, 99%), 40% (95% CI: 8%, 81%), 31% (95% CI: 2%, 68%), 23% (95% CI: 2%, 49%), and 6% (95% CI: 1%, 12%) increase in cord TSH concentrations, respectively (Figure 3). We also observed an increase in cord T3RU and FT₄ concentrations in relation to some PFAS, though most of these associations did not reach the level of significance. Moreover, higher concentrations of PFOS, PFDA, PFNA, and FOSA were associated with higher cord FTI levels. For instance, a two-fold increase in PFNA and PFDA was associated with an 8% (95% CI: 0%, 17%) and 8% (95% CI: 1%, 17%) increase in cord FTI, respectively.

We observed significant effect modification (p-interaction<0.1) by child sex in the association between PFOA and cord serum-FTI and T₄ concentrations (Figure 3). A doubling in gestational PFOA concentration was associated with an 11% (95% CI: 2%, 20%) increase in cord FTI levels in girls, in comparison to a decrease by 5% (95% CI: -13%, 3%) in boys (p-EM=0.02) (44). The same pattern was observed for associations between PFOA and cord T₄ levels.

Insert Figure 3. [HERE]

Mediation analyses.

We investigated whether THs potentially mediate some of the effects found between PFAS and birth size. Although a few THs such as FTI and T₄ were found to partially mediate the effect of
certain PFAS on birth weight and length (ACME of FTI in the association between PFNA and birth weight = 0.10, 95% CI: 0.00, 0.25), overall, values of the mediated effects (ACME) and the proportion mediated (PM) were consistently non-significant and close to null for all outcomes and PFAS exposures (44). Thus, THs did not appear to explain the observed associations between PFAS and birth outcomes in this Faroese cohort.

**Discussion**

In this study of 172 mother-infant pairs from the Faroe Islands, we found negative associations between gestational exposure to certain PFAS and birth weight, birth length, and, to a lesser extent, head circumference. Of the PFAS that were associated with these birth size outcomes, we also found PFAS to be consistently associated with increased cord and maternal serum TSH concentrations, thus suggesting that alterations in TSH levels may be a potential pathway linking PFAS exposure to reduced birth weight, birth length, and head circumference. We did not find a generalized pattern for associations between PFAS and other THs. THs did not appear to mediate the associations between any PFAS and fetal growth outcome.

Recent studies and systematic reviews of epidemiological evidence reported that increases in PFAS concentrations during pregnancy were associated with lower birth weight (10-17,19-24), also in line with our findings in this study as well as our study in a younger Faroese cohort born in 1997-2000 (25). In the previous study, we found non-significant inverse associations between PFAS exposure and birth weight in both single-PFAS linear regression analysis and using SEMs (mean change per doubling of PFAS exposure: -169 g, 95% CI: -359, 21), which is slightly lower than the estimates found in this current study. In addition, a study conducted on a Japanese cohort found similar results, as they reported a decrease of -197 g (95% CI: -391, -3) in birth
weight in association to PFOA (16). Another study found that PFOA and PFNA were associated with a decrease of approximately 50 grams in birth weight after adjustment for covariates (7,15). Furthermore, a cohort study conducted on a Swedish population, a population comparable to that in the Faroe Islands, reported a decrease of -359 g (95% CI: -596, -122) and -292 g (95% CI: -500, -84) in birth weight per ln-unit increase in PFOA and PFOS, respectively (50). Our results on PFOA, PFOS, and birth weight are consistent with these results, although the magnitude of change in birth weight is lower than that in the Swedish study.

We did not observe the associations between PFAS and birth weight to differ by child sex. Some studies, including our previous investigation in the younger Faroese cohort, showed that prenatal exposure to PFOA and/or PFOS was negatively associated with birth weight in boys but not in girls (14,25,50,51). However, other studies have reported no clear effect modification by sex (15) or associations only in girls (21). It is thus unclear whether the absence of significant modification by sex in the present study reflects the true effect or is it due to the small sample size and limited power.

Fewer studies have examined associations between PFAS and either birth length or head circumference. In our previous study of a younger Faroese cohort, we found that PFAS tended to be inversely associated with head circumference, though these estimates did not reach significance (25). A study that was conducted in Sweden reported an inverse association of PFAS exposure with birth length and head circumference, although only associations with birth length were significant. For each ln-unit increase in PFOA, birth length decreased by -1.3 cm (95% CI: -2.3, -0.3), while for each ln-unit increase in PFOS, birth length decreased by -1.2 cm
(95% CI: -2.1, -0.3) in head circumference (50). A study of a Spanish cohort concluded that PFAS such as PFHxS, PFOA, and PFNA and PFOS were not significantly associated with either birth length or head circumference (14). A further study found that PFDoDA was inversely associated with head circumference, though only in girls (52). Our findings are in line with the findings from the Swedish cohort, as we also found negative yet insignificant associations between PFOA and PFOS with head circumference.

Previous studies have identified PFAS to be a potential thyroid disruptor during pregnancy, influencing maternal and offspring TH levels (8,9,29–35). Two systematic reviews concluded that, in general, PFAS were positively associated with TSH, while the associations between PFAS and total and free T3 and T4 were less consistent (8,9). Our results are consistent with these findings, as we observed that higher PFAS concentrations were associated with changes in certain TH levels, namely TSH, during pregnancy and at birth, and less consistently with free and total T3 and T4. PFAS are thought to affect thyroid hormone homeostasis by competing with T3 and T4 for their binding proteins (53,54), which may result in a decrease of thyroid hormone levels, which in turn may induce a compensatory increase in TSH levels (55). This hypothesis is supported by positive associations shown between PFAS and TSH in this investigation and previous studies (8,9).

We also observed the effect of PFAS exposure on THs to differ based on whether the mother was carrying a male or female fetus, as we found that PFOS and PFOA were positively associated with THs in mothers carrying female fetuses and negatively associated with mothers carrying male fetuses. While it is yet unclear how the sex of the child may influence PFAS-
associated maternal thyroid hormone dysfunction, it is worth corroborating these findings in future studies examining other populations. Further analysis should be undertaken to determine the mechanisms for such differences in maternal hormone levels and whether they have any health implications. Another consideration is that any potential sex-specific effects may also reduce the power for detecting significant mediating effects.

We did not find THs to mediate the relationship between PFAS exposure and birth size. This may be due to a number of factors, including small sample size, as well as the effect of THs to explain only a very small part of the PFAS-birth size association. Furthermore, TH concentrations were measured at a single point in time during pregnancy and at birth, which may have introduced some measurement error due to physiological variations. Other potential hormones should be further explored as mediators, such as adipokine hormones that also play an important role in growth and development, and that have also been associated to prenatal PFAS exposure (16,19,56).

To our knowledge, this is the first study examining the potential of THs to mediate associations between PFAS and birth size. Important strengths of this study include that we used a population-based birth cohort with elevated PFAS exposures from seafood intake to evaluate a wide range of thyroid parameters in mother-singleton birth pairs as well as a larger panel of PFAS than commonly examined. Due to the high intake of seafood, this population is believed to be without iodine deficiency that might have affected thyroid functions. Moreover, we included analyses on T3RU and FTI as indirect measures of TH binding in relation to PFAS exposure.
Furthermore, since the Faroe Islands has a relatively homogenous population in terms of SES, results are less likely to be due to residual confounding.

Potential study limitations include the small sample size used in this analysis. Furthermore, TH concentrations measured from cord blood during late gestation may not be an accurate marker of fetal TH levels, because cord TH measurement can be influenced by maternal TH levels, can change until shortly after birth, and can be influenced by mode and time of delivery (9,57). We also found associations between FT₄ and TH levels to be non-significant and associations between FTI and TH levels to be significant. There are some discussions about the inclusion and reliability of FTI calculations to assess TH levels during pregnancy (58–61); thus associations between FTI and TH levels should be treated with caution. Regardless of significance, however, associations were found to be in the same direction for both TH markers, and thus results should not be considered contradictory or inconsistent. The null findings for FT₄ and significant findings for FTI can be potentially attributed to differences in measurement error, which may have attenuated the findings for FT₄. Imprecision may not have been an important issue for the PFAS measurement, as PFAS examined in the main analyses have relatively long half-lives and thus these measurements can be considered as reliable estimates. However, we did observe low assay detection of a few PFAS and their precursors, including PFHpA, PFDoDA, and FOSA. Thus, results for these PFAS should be treated with caution.

Other limitations include the lack of information on iodine status that may confound the TH-birth size associations. However, we can assume that because the Faroese population generally consumes a high quantity of seafood, they should not be iodine-deficient (38,43). In addition, as
we included only mostly term-births and infants with birth weights greater than 2500 grams, our findings may not be generalized to preterm or low-birth weight births. Finally, because several PFAS were found to be highly intercorrelated, our results may be subject to confounding among PFAS. We also did not consider whether PFAS mixtures can exhibit different effects on fetal growth outcomes and TH concentrations, when mothers and fetuses are exposed to multiple PFAS.

Conclusions

In an ethnically homogenous Faroese birth cohort, we found that prenatal exposures to several PFAS were inversely associated with birth weight, birth length, and cranial circumference. PFAS were generally positively associated with cord serum-TSH concentrations; however, the effect of PFAS concentrations on birth size measures did not appear to be mediated through changes in THs.

Acknowledgments

We thank Ulrike Steuerwald for performing the clinical examinations and the cohort families for their support of the study.

Financial support: This work was supported by the National Institute of Environmental Health Sciences (ES011681, ES012199 and ES027706) and the Danish Environmental Protection Agency as part of the environmental support program DANCEA (Danish Cooperation for Environment in the Arctic).

Author Contributions: C.X. conducted the data analysis, prepared the figures and tables, and wrote the manuscript under supervision of YO. C.X., Y.O., and P.G. conceptualized the study.
P.G. and P.W. initiated the cohort, recruited the participants, and conducted subsequent follow-up. F.N. conducted the PFAS analyses. C.X., P.G., D.V., FN., T.K.J., and Y.O. contributed in data interpretation, validated the findings, and critically reviewed the manuscript.

References


doi:10.1021/es202408a


54. Weiss JM, Andersson PL, Lamoree MH, Leonards PEG, van Leeuwen SPJ, Hamers T.
doi:10.1093/toxsci/kfp055


doi:10.1089/thy.2016.0457
Figure Legends

Figure 1. Estimates and 95% confidence intervals for the associations between perfluoroalkyl substance concentrations and fetal growth outcomes stratified by child sex. Models were adjusted for child gender, parity, maternal body mass index, maternal height, maternal education, maternal age, smoking and drinking alcohol during pregnancy, total PCB, and mercury; sex was not adjusted for in the sex-stratified analyses. Perfluoroalkyl substance were log$_2$-transformed, while thyroid hormones were log-transformed to fit a normal distribution.

Figure 2. Percent change in maternal thyroid hormone levels per doubling of perfluoroalkyl substances concentrations with 95% confidence intervals stratified by child sex. Models were adjusted for child gender, parity, maternal body mass index, maternal education, maternal age, smoking and drinking alcohol during pregnancy, total PCB, and mercury; sex was not adjusted for in the sex-stratified analyses. Perfluoroalkyl substances were log$_2$-transformed, while thyroid hormones were log-transformed to fit a normal distribution.

Figure 3. Percent change in cord thyroid hormone levels per doubling of perfluoroalkyl substances concentrations with 95% confidence intervals stratified by child sex. Models were adjusted for child gender, parity, maternal body mass index, maternal education, maternal age, smoking and drinking alcohol during pregnancy, total PCB, and mercury; sex was not adjusted for in the sex-stratified analyses. Perfluoroalkyl substances were log$_2$-transformed, while thyroid hormones were log-transformed to fit a normal distribution.
Table 1. Cohort description and covariates of interest

<table>
<thead>
<tr>
<th>Covariate</th>
<th>n</th>
<th>(mean ± SD) / %*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Child Characteristics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex (boy/girl)</td>
<td>172</td>
<td>50.6/49.4</td>
</tr>
<tr>
<td>Gestational age, weeks</td>
<td>170</td>
<td>39.6 ± 1.3</td>
</tr>
<tr>
<td>Birth weight, g</td>
<td>172</td>
<td>3671.5 ± 485.2</td>
</tr>
<tr>
<td>Birth length, cm</td>
<td>172</td>
<td>53.0 ± 2.1</td>
</tr>
<tr>
<td>Head circumference, cm</td>
<td>153</td>
<td>35.6 ± 1.4</td>
</tr>
<tr>
<td><strong>Maternal Characteristics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maternal age, years</td>
<td>171</td>
<td>28.1 ± 5.6</td>
</tr>
<tr>
<td>Maternal education (≥ some higher education)</td>
<td>167</td>
<td>21.6</td>
</tr>
<tr>
<td>Maternal BMI, kg/m²</td>
<td>172</td>
<td>23.1 ± 3.5</td>
</tr>
<tr>
<td>Weight gain during pregnancy, kg</td>
<td>164</td>
<td>14.4 ± 4.7</td>
</tr>
<tr>
<td>Parity (primiparous/multiparous)</td>
<td>172</td>
<td>28.5/71.5</td>
</tr>
<tr>
<td>ΣPCB, ug/g</td>
<td>169</td>
<td>1.6 ± 1.8</td>
</tr>
<tr>
<td>Hair mercury, ug/g</td>
<td>140</td>
<td>5.4 ± 3.6</td>
</tr>
<tr>
<td>Alcohol consumption during pregnancy (yes/no)</td>
<td>172</td>
<td>12.8/ % for alcohol drinkers</td>
</tr>
<tr>
<td>Smoking during pregnancy (yes/no)</td>
<td>172</td>
<td>31.3/ % for non-smokers</td>
</tr>
</tbody>
</table>

*Estimates are presented as (mean ± SD) for continuous variables and percentages (%) for categorical variables.
Table 2. Distribution of different PFAS concentrations in the cohort (n = 172)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Acronym</th>
<th>% &lt; LOD</th>
<th>Concentration (µg/g)</th>
<th>Geometric Mean (GSE)</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carboxylic acids (PFCAs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perfluoroheptanoic acid</td>
<td>PFHpA</td>
<td>53%</td>
<td>0.03 (&lt;0.01)</td>
<td>0.0 - 0.5</td>
<td></td>
</tr>
<tr>
<td>Perfluorooctanoic acid</td>
<td>PFOA</td>
<td>0%</td>
<td>2.37 (0.07)</td>
<td>0.8 - 6.9</td>
<td></td>
</tr>
<tr>
<td>Perfluorononanoic acid</td>
<td>PFNA</td>
<td>0%</td>
<td>0.60 (0.02)</td>
<td>0.2 - 1.6</td>
<td></td>
</tr>
<tr>
<td>Perfluorodecanoic acid</td>
<td>PFDA</td>
<td>0%</td>
<td>0.30 (0.01)</td>
<td>0.1 - 0.9</td>
<td></td>
</tr>
<tr>
<td>Perfluoroundecanoic acid</td>
<td>PFUnDA</td>
<td>0%</td>
<td>0.47 (0.02)</td>
<td>0.1 - 1.8</td>
<td></td>
</tr>
<tr>
<td>Perfluorododecanoic acid</td>
<td>PFDDoDA</td>
<td>68%</td>
<td>0.03 (&lt;0.01)</td>
<td>0.0 - 0.5</td>
<td></td>
</tr>
<tr>
<td>Sulfonic acids (PFSAs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perfluorohexane sulfonic acid</td>
<td>PFHxS</td>
<td>0%</td>
<td>0.55 (0.02)</td>
<td>0.1 - 2.8</td>
<td></td>
</tr>
<tr>
<td>Perfluoroheptane sulfonic acid</td>
<td>PFHpS</td>
<td>7%</td>
<td>0.35 (0.03)</td>
<td>0.0 - 1.4</td>
<td></td>
</tr>
<tr>
<td>Perfluorooctane sulfonic acid</td>
<td>PFOS</td>
<td>0%</td>
<td>20.86 (0.47)</td>
<td>6.9 - 47.6</td>
<td></td>
</tr>
<tr>
<td>PFAS precursors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-ethyl perfluorooctane sulfonamide</td>
<td>NEtFOSAA</td>
<td>0%</td>
<td>0.65 (0.03)</td>
<td>0.0 - 1.8</td>
<td></td>
</tr>
<tr>
<td>N-methyl perfluorooctane sulfonamide</td>
<td>NMMeFOSAA</td>
<td>0%</td>
<td>0.18 (0.01)</td>
<td>0.0 - 1.8</td>
<td></td>
</tr>
<tr>
<td>Perfluorooctane sulfonamide</td>
<td>FOSA</td>
<td>63%</td>
<td>0.04 (&lt;0.01)</td>
<td>0.0 - 1.2</td>
<td></td>
</tr>
</tbody>
</table>

Note: GSE, Geometric Standard Error; LOD, Limit of Detection. PFDS, PFPeA, PFHxA, PFBA, and PFBS were also quantified but levels did not meet the LOD limit.
Table 3. Thyroid parameters and birth size of the Faroese birth cohort

<table>
<thead>
<tr>
<th>Thyroid parameters</th>
<th>n</th>
<th>Geometric mean (SE)</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal Serum</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TSH (IU/L)</td>
<td>172</td>
<td>1.34 (0.05)</td>
<td>0.23 – 3.61</td>
</tr>
<tr>
<td>FT₄ (pmol/L)</td>
<td>172</td>
<td>8.18 (0.11)</td>
<td>5.49 – 14.70</td>
</tr>
<tr>
<td>FT₃ (pmol/L)</td>
<td>172</td>
<td>4.25 (0.05)</td>
<td>2.94 – 6.62</td>
</tr>
<tr>
<td>T₄ (nmol/L)</td>
<td>172</td>
<td>121.08 (1.95)</td>
<td>61.00 – 224.00</td>
</tr>
<tr>
<td>T₃RU</td>
<td>172</td>
<td>0.66 (0.01)</td>
<td>0.51 – 1.01</td>
</tr>
<tr>
<td>FTI (IU/L)</td>
<td>172</td>
<td>80.47 (1.16)</td>
<td>53.00 – 164.00</td>
</tr>
<tr>
<td>Cord Serum</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TSH (IU/L)</td>
<td>153</td>
<td>6.98 (0.33)</td>
<td>2.03 – 27.40</td>
</tr>
<tr>
<td>FT₄ (pmol/L)</td>
<td>153</td>
<td>11.93 (0.36)</td>
<td>0.38 – 16.60</td>
</tr>
<tr>
<td>FT₃ (pmol/L)</td>
<td>153</td>
<td>2.35 (0.04)</td>
<td>2.00 – 5.54</td>
</tr>
<tr>
<td>T₄ (nmol/L)</td>
<td>153</td>
<td>129.07 (1.92)</td>
<td>68.00 – 205.00</td>
</tr>
<tr>
<td>T₃RU</td>
<td>153</td>
<td>0.83 (0.01)</td>
<td>0.54 – 1.05</td>
</tr>
<tr>
<td>FTI (IU/L)</td>
<td>153</td>
<td>107.60 (1.47)</td>
<td>65.00 – 191.00</td>
</tr>
<tr>
<td>Birth size</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Birth Weight, g</td>
<td>171</td>
<td>3672.0 (37.0)</td>
<td>2500.0 – 4800.0</td>
</tr>
<tr>
<td>Birth Length, cm</td>
<td>171</td>
<td>53 (0.2)</td>
<td>48.0-59.0</td>
</tr>
<tr>
<td>Head Circumference, cm</td>
<td>152</td>
<td>35.6 (.01)</td>
<td>31.5 – 39.0</td>
</tr>
</tbody>
</table>

Note: SE, Standard error; SD, Standard deviation
Figure 1. Estimates and 95% confidence intervals for the associations between perfluoroalkyl substance concentrations and fetal growth outcomes stratified by child sex.
Figure 2. Percent change in maternal thyroid hormone levels per doubling of perfluoroalkyl substance concentrations with 95% confidence intervals stratified by population.
Figure 3. Percent change in cord thyroid hormone levels per doubling of perfluoroalkyl substance concentrations with 95% confidence intervals stratified by child sex.